(R, S)-and (S)-ketamine have made significant progress in the treatment of treatment-
resistant depression (TRD) and have become a research focus in recent years. However …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Abstract Background and Aims Ketamine and esketamine have garnered interest in both
psychiatric research and clinical practice for treatment-resistant depression (TRD). In this …

ABSTRACT Introduction: Treatment Resistant Depression (TRD) is a common and
burdensome condition with poor outcomes and few treatment options. Esketamine is the S …

Background There is an urgent need to develop additional treatment strategies for patients
with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of …

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for
patients with treatment-resistant depression was a serendipitous finding, clinical use of …

I read with great interest the recent article by Kishimoto et al.(2016) about meta-analysis of
the antidepressant effects of the N-methyl-D-aspartate receptor (NMDA-R) antagonist …

Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce
a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes …

Background: Ketamine has been reported to exert rapid and sustained antidepressant
effects in patients with depression, including patients with treatment-resistant depression …

The robust antidepressant effects of (R, S)-ketamine are among the most important
discoveries in mood research over the last half century. Off-label use of (R, S)-ketamine …